{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:39Z","timestamp":1789495659505,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"secretaria de investigaci\u00f3n y posgrado del Instituto Polit\u00e9cnico Nacional","award":["20240883"],"award-info":[{"award-number":["20240883"]}]},{"name":"secretaria de investigaci\u00f3n y posgrado del Instituto Polit\u00e9cnico Nacional","award":["20240883"],"award-info":[{"award-number":["20240883"]}]},{"name":"secretaria de investigaci\u00f3n y posgrado del Instituto Polit\u00e9cnico Nacional","award":["20240883"],"award-info":[{"award-number":["20240883"]}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020417","name":"Consejo Mexiquense de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["CAT2024-0077"],"award-info":[{"award-number":["CAT2024-0077"]}],"id":[{"id":"10.13039\/501100020417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite the advances made in diagnosing and treating breast cancer, it continues to pose a significant threat to women\u2019s health. High-risk mutations can lead to high resistance to current treatments and poor prognosis. Therefore, new treatment strategies are needed. Mangiferin and silybin, two natural substances obtained from plants, have demonstrated encouraging results as anticancer drugs. This study investigated the activity of these compounds against two therapeutic targets, human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). We assessed the binding affinity and stability of these compounds with the active sites of wild-type and mutated HER2 and EGFR by using computational screening techniques, namely molecular docking, density functional theory, and molecular dynamics (MD) simulations with the MMGBSA method. We used molecular docking, triplicate MD simulations summing 300 ns each, and density functional theory analysis to estimate the binding mechanism of mangiferin and silybin inside the wild-type and mutated EGFR and HER2 active regions. Moreover, an in vitro experiment showed that mangiferin and silybin inhibited the growth of two HER2-positive breast cancer cell lines, BT-474 and SK-BR-3, at micromolar concentrations. These findings suggest the potential for developing novel anticancer therapies that specifically target EGFR and HER2.<\/jats:p>","DOI":"10.1038\/s41598-025-93612-2","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:10:38Z","timestamp":1741853438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Insight into the inhibitory activity of mangiferin and Silybin against HER2 and EGFR using theoretical and experimental approaches"],"prefix":"10.1038","volume":"15","author":[{"given":"Jes\u00fas Eduardo","family":"Alvarado-Lozano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Arturo","family":"Hern\u00e1ndez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Daniel","family":"\u00c1vila-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martiniano","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"93612_CR1","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"MA Olayioye","year":"2000","unstructured":"Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The erbb signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19, 3159\u20133167 (2000).","journal-title":"EMBO J."},{"key":"93612_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000279388","volume":"77","author":"G Lurje","year":"2009","unstructured":"Lurje, G. & Lenz, H. J. EGFR signaling and drug discovery. Oncology 77, 400\u2013410 (2009).","journal-title":"Oncology"},{"key":"93612_CR3","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","volume":"16","author":"E Tzahar","year":"1996","unstructured":"Tzahar, E. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu diferentiation factor\/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276\u20135287 (1996).","journal-title":"Mol. Cell. Biol."},{"key":"93612_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/bies.20582","volume":"29","author":"DJ Riese","year":"2007","unstructured":"Riese, D. J. 2, Gallo, R. M., Settleman, J. & nd, & Mutational activation of erbb family receptor tyrosine kinases: Insights into mechanisms of signal transduction and tumorigenesis. BioEssays 29, 558\u2013565 (2007).","journal-title":"BioEssays"},{"key":"93612_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pharma.2010.03.007","volume":"68","author":"F Cruzalegui","year":"2010","unstructured":"Cruzalegui, F. Protein kinases: From targets to Anti-Cancer drugs. Ann. Pharm. Fr. 68, 254\u2013259 (2010).","journal-title":"Ann. Pharm. Fr."},{"key":"93612_CR6","doi-asserted-by":"publisher","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","volume":"286","author":"K Aertgeerts","year":"2011","unstructured":"Aertgeerts, K. et al. Structural analysis of the mechanism of Inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 286, 18756\u201318765 (2011).","journal-title":"J. Biol. Chem."},{"key":"93612_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00894-021-04720-5","volume":"27","author":"M Bello","year":"2021","unstructured":"Bello, M. Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2. J. Mol. Model. 27, 105 (2021).","journal-title":"J. Mol. Model."},{"key":"93612_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033583508004745","volume":"42","author":"LN Johnson","year":"2009","unstructured":"Johnson, L. N. Protein kinase inhibitors: Contributions from structure to clinical compounds. Q. Rev. Biophys. 42, 1\u201340 (2009).","journal-title":"Q. Rev. Biophys."},{"key":"93612_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2008.11.008","volume":"281","author":"A Torkamani","year":"2009","unstructured":"Torkamani, A., Verkhivker, G. & Schork, N. J. Cancer driver mutations in protein kinase genes. Cancer Lett. 281, 117\u2013127 (2009).","journal-title":"Cancer Lett."},{"key":"93612_CR10","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).","journal-title":"PLoS Med."},{"key":"93612_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1158\/1078-0432.CCR-07-4367","volume":"14","author":"T Trowe","year":"2008","unstructured":"Trowe, T. et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin. Cancer Res. 14, 2465\u20132475 (2008).","journal-title":"Clin. Cancer Res."},{"key":"93612_CR12","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-08-3953","volume":"69","author":"ER Wood","year":"2009","unstructured":"Wood, E. R. et al. Equally potent Inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69, 2384\u20132392 (2009).","journal-title":"Cancer Res."},{"key":"93612_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/157340611794072698","volume":"7","author":"QH Liao","year":"2011","unstructured":"Liao, Q. H., Gao, Q. Z., Wei, J. & Chou, K. C. Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Med. Chem. 7, 24\u201331 (2011).","journal-title":"Med. Chem."},{"key":"93612_CR14","first-page":"521","volume":"14","author":"N Mahmoodi","year":"2015","unstructured":"Mahmoodi, N., Motamed, N., Paylakhi, S. H. & Mahmoodi, O. Comparing the effect of Silybin and Silybin advanced\u2122 on viability and HER2 expression on the human breast Cancer SKBR3 cell line by no serum starvation. Iran. J. Pharm. Res. Spring. 14, 521\u2013530 (2015).","journal-title":"Iran. J. Pharm. Res. Spring"},{"key":"93612_CR15","first-page":"471","volume":"13","author":"KM Yap","year":"2021","unstructured":"Yap, K. M. et al. Mangifera indica (Mango): A promising medicinal plant for breast Cancer therapy and Understanding its potential mechanisms of action. Breast Cancer (Dove Med. Press). 13, 471\u2013503 (2021).","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"93612_CR16","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.4238\/2015.May.12.2","volume":"14","author":"ZG Peng","year":"2015","unstructured":"Peng, Z. G., Yao, Y. B., Yang, J., Tang, Y. L. & Huang, X. Mangiferin induces cell cycle arrest at G2\/M phase through ATR-Chk1 pathway in HL-60 leukemia cells. Genet. Mol. Research: GMR. 14, 4989\u20135002 (2015).","journal-title":"Genet. Mol. Research: GMR"},{"key":"93612_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.taap.2013.05.011","volume":"272","author":"H Li","year":"2013","unstructured":"Li, H. et al. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and b-catenin signaling pathway. Toxicol. Appl. Pharmcol. 272, 180\u2013190 (2013).","journal-title":"Toxicol. Appl. Pharmcol."},{"key":"93612_CR18","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.1080\/07391102.2021.1975570","volume":"40","author":"TA Balogun","year":"2022","unstructured":"Balogun, T. A. et al. Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach. J. Biomol. Struct. Dyn. 40, 12772\u201312784 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"93612_CR19","unstructured":"Molecular Operating Environment (MOE) 2022.02, Chemical Computing Group ULC: 910\u20131010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada, (2023)."},{"key":"93612_CR20","unstructured":"DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Francisco, CA, USA; Palo Alto: Santa Clara, CA, USA, (2002)."},{"key":"93612_CR21","doi-asserted-by":"publisher","first-page":"W270","DOI":"10.1093\/nar\/gkr366","volume":"39","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule Docking web service based on EADock DSS. Nucleic Acids Res. 39, W270\u2013W277 (2011).","journal-title":"Nucleic Acids Res."},{"key":"93612_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2946-4-17","volume":"4","author":"MD Hanwell","year":"2012","unstructured":"Hanwell, M. D. et al. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminf. 4, 1\u201317 (2012).","journal-title":"J. Cheminf"},{"key":"93612_CR23","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"93612_CR24","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1063\/1.1667473","volume":"120","author":"BP Uberuaga","year":"2004","unstructured":"Uberuaga, B. P., Anghel, M. & Voter, A. F. Synchronization of trajectories in canonical molecular-dynamics simulations: observation, explanation, and exploitation. J. Chem. Phys. 120, 6363\u20136374 (2004).","journal-title":"J. Chem. Phys."},{"key":"93612_CR25","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1021\/ct800573m","volume":"5","author":"DJ Sindhikara","year":"2009","unstructured":"Sindhikara, D. J., Kim, S., Voter, A. F. & Roitberg, A. E. Bad seeds sprout perilous dynamics: Stochastic thermostat induced trajectory synchronization in biomolecules. J. Chem. Theory Comput. 5, 1624\u20131631 (2009).","journal-title":"J. Chem. Theory Comput."},{"key":"93612_CR26","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N\u00b7log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089\u201310092 (1993).","journal-title":"J. Chem. Phys."},{"key":"93612_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"JP Ryckaert","year":"1997","unstructured":"Ryckaert, J. P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341 (1997).","journal-title":"J. Comput. Phys."},{"key":"93612_CR28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case, D. A. et al. The amber biomolecular simulation programs. J. Comput. Chem. 26, 1668\u20131688 (2005).","journal-title":"J. Comput. Chem."},{"key":"93612_CR29","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller 3rd","year":"2012","unstructured":"Miller, B. R. 3rd et al. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314\u20133321 (2012).","journal-title":"J. Chem. Theory Comput."},{"key":"93612_CR30","doi-asserted-by":"publisher","first-page":"25118","DOI":"10.1039\/D3RA04916G","volume":"13","author":"M Bello","year":"2023","unstructured":"Bello, M. & Bandala, C. Evaluating the ability of end-point methods to predict the binding affinity tendency of protein kinase inhibitors. RSC Adv. 13, 25118\u201325128 (2023).","journal-title":"RSC Adv."},{"key":"93612_CR31","unstructured":"Frisch, M. J. et al. Gaussian 09, Revision A.02 (Gaussian, Inc., 2016)."},{"key":"93612_CR32","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1063\/1.475007","volume":"107","author":"AD Becke","year":"1997","unstructured":"Becke, A. D. Density-functional thermochemistry. V. Systematic optimization of exchange-correlation functionals. J. Chem. Phys. 107, 8554\u20138560 (1997).","journal-title":"J. Chem. Phys."},{"key":"93612_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1107\/S0021889811038970","volume":"44","author":"K Momma","year":"2011","unstructured":"Momma, K. & Izumi, F. VESTA\u20053 for three-dimensional visualization of crystal, volumetric and morphology data. J. Appl. Crystallogr. 44, 1272\u20131276 (2011).","journal-title":"J. Appl. Crystallogr."},{"key":"93612_CR34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10822-017-0042-5","volume":"31","author":"G Schaftenaar","year":"2017","unstructured":"Schaftenaar, G., Vlieg, E. & Vriend, G. Molden 2.0: quantum chemistry Meets proteins. J. Comput. Aided Mol. Des. 31, 789\u2013800 (2017).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"93612_CR35","unstructured":"Inostroza, D., Y\u00e1\u00f1ez, O., Pino, R. & Tiznado, W. Software for the topological analysis of the Fukui function (TAFF). Proceedings of MOL2NET 2016, International Conference on Multidisciplinary Sciences, 2nd Edition. (2016)."},{"key":"93612_CR36","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1557\/s43579-023-00455-x","volume":"13","author":"RD \u00c1vila-Avil\u00e9s","year":"2023","unstructured":"\u00c1vila-Avil\u00e9s, R. D. Quantum chemical analysis of isomerization and protonation of amino group in D-glucosamine. MRS Commun. 13, 1303\u20131308 (2023).","journal-title":"MRS Commun."},{"key":"93612_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1557\/s43580-023-00504-6","volume":"8","author":"RD \u00c1vila-Avil\u00e9s","year":"2023","unstructured":"\u00c1vila-Avil\u00e9s, R. D. & Vilchis-Nestor, A. R. Theoretical study on the interactions of Anemopsis californica compounds with graphene monolayers: A DFT perspective. MRS Adv. 8, 95\u2013102 (2023).","journal-title":"MRS Adv."},{"key":"93612_CR38","doi-asserted-by":"crossref","unstructured":"\u00c1vila-Avil\u00e9s, R. D., Bahena-Culhuac, E. & Hern\u00e1ndez-Hern\u00e1ndez, J. M. (-)-Epicatechin metabolites as a GPER ligands: a theoretical perspective. Mol. Diversity (2024).","DOI":"10.1007\/s11030-024-10968-9"},{"key":"93612_CR39","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.3390\/ijms21113922","volume":"21","author":"M Hagar","year":"2020","unstructured":"Hagar, M., Ahmed, H. A., Aljohani, G. & Alhaddad, O. A. Investigation of some antiviral N heterocycles as COVID 19 drug: Molecular Docking and DFT calculations. Int. J. Mol. Sci. 21, 3922 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"93612_CR40","doi-asserted-by":"publisher","first-page":"133651","DOI":"10.1016\/j.molstruc.2022.133651","volume":"1268","author":"A Zochedh","year":"2022","unstructured":"Zochedh, A., Priya, M., Shunmuganarayanan, A., Thandavarayan, K. & Sultan, A. B. Investigation on structural, spectroscopic, DFT, biological activity and molecular Docking simulation of essential oil Gamma-Terpinene. J. Mol. Struct. 1268, 133651 (2022).","journal-title":"J. Mol. Struct."},{"key":"93612_CR41","doi-asserted-by":"crossref","unstructured":"Fuentealba, P., Cardenas, C., Pino-Rios, R. & Tiznado, W. Topological Analysis of the Fukui Function in Applications of Topological Methods in Molecular Chemistry. Challenges and Advances in Computational Chemistry and Physicsvol 22 (Springer, 2016).","DOI":"10.1007\/978-3-319-29022-5_8"},{"key":"93612_CR42","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1021\/jp990092i","volume":"103","author":"J Aihara","year":"1999","unstructured":"Aihara, J. Reduced HOMO\u2009\u2013\u2009LUMO gap as an index of kinetic stability for polycyclic aromatic hydrocarbons. J. Phys. Chem. A. 103, 7487\u20137495 (1999).","journal-title":"J. Phys. Chem. A"},{"key":"93612_CR43","doi-asserted-by":"crossref","unstructured":"Uzzaman, M. & Jabedul, M. Physiochemical, molecular docking, and Pharmacokinetic studies of Naproxen and its modified derivatives based on DFT. Int. J. Sci. Res. Manage. 6, (2018).","DOI":"10.18535\/ijsrm\/v6i9.c01"},{"key":"93612_CR44","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1021\/jp9638705","volume":"101","author":"GI C\u00e1rdenas-Jir\u00f3n","year":"1997","unstructured":"C\u00e1rdenas-Jir\u00f3n, G. I., Guti\u00e9rrez-Oliva, S., Melin, J.  & Toro-Labb\u00e9, A. Relations between potential energy, electronic chemical potential, and hardness profiles. J. Phys. Chem. A. 101, 4621\u20134627 (1997).","journal-title":"J. Phys. Chem. A"},{"key":"93612_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molliq.2018.05.114","volume":"265","author":"U Srimathi","year":"2018","unstructured":"Srimathi, U., Nagarajan, V. & Chandiramouli, R. Interaction of Imuran, Pentasa and hyoscyamine drugs and solvent effects on Graphdiyne nanotube as a drug delivery system - A DFT study. J. Mol. Liq. 265, 199\u2013207 (2018).","journal-title":"J. Mol. Liq."},{"key":"93612_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10822-019-00270-4","volume":"34","author":"M Bello","year":"2020","unstructured":"Bello, M., Guadarrama-Garc\u00eda, C. & Rodriguez-Fonseca, R. A. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR\/HER2. J. Comput. Aided Mol. Des. 34, 293\u2013303 (2020).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"93612_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijbiomac.2017.12.162","volume":"111","author":"M Bello","year":"2018","unstructured":"Bello, M., Salda\u00f1a-Rivero, L., Correa-Basurto, J.,  Garc\u00eda, B. & S\u00e1nchez-Espinosa, V. A. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR\/HER2. Int. J. Biol. Macromol. 111, 569\u2013586 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"93612_CR48","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.ijbiomac.2018.07.042","volume":"118","author":"M Bello","year":"2018","unstructured":"Bello, M. Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R\/T790M mutants through structural and energetic analysis. Int. J. Biol. Macromol. 118, 1948\u20131962 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"93612_CR49","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1080\/07391102.2018.1558112","volume":"37","author":"L Salda\u00f1a-Rivera","year":"2019","unstructured":"Salda\u00f1a-Rivera, L., Bello, M. & M\u00e9ndez-Luna, D. Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R\/T790 mutants. J. Biomol. Struct. Dyn. 37, 4671 4684 (2019).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"93612_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jmgm.2013.06.004","volume":"44","author":"M Ahmed","year":"2013","unstructured":"Ahmed, M., Sadek, M. M., Abouzid, K. A. & Wang, F. In Silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. J. Mol. Graph Model. 44, 220\u2013231 (2013).","journal-title":"J. Mol. Graph Model."},{"key":"93612_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.gde.2010.10.012","volume":"21","author":"J Brognard","year":"2011","unstructured":"Brognard, J. & Hunter, T. Protein kinase signaling networks in Cancer. Curr. Opin. Genet. Dev. 21, 4\u201311 (2011).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"93612_CR52","doi-asserted-by":"crossref","unstructured":"Mortlock, A., Foote, K., Kettle, J. & Aquila, B. Kinase Inhibitors in Cancer in Reference Module in Chemistry, Molecular Sciences and Chemical Engineering (Elsevier Ltd, 2014).","DOI":"10.1016\/B978-0-12-409547-2.11033-9"},{"key":"93612_CR53","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd1579","volume":"3","author":"H Daub","year":"2004","unstructured":"Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discovery. 3, 1001\u20131010 (2004).","journal-title":"Nat. Rev. Drug Discovery"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93612-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:30:59Z","timestamp":1741854659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93612"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93612-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8658"}}